Cell-penetrating heme oxygenase-1 in the therapy of atopic dermatitis in mice

xlomafota13 shared this article with you from Inoreader Cell-penetrating heme oxygenase-1 in the therapy of atopic dermatitis in mice Via Experimental and therapeutic medicine Exp Ther Med. 2021 Sep;22(3):941. doi: 10.3892/etm.2021.10373. Epub 2021 Jul 1. ABSTRACT Atopic dermatitis (AD), also referred to as atopic eczema, is a long-term inflammatory condition that is characterized by itchy, red, swollen and cracked skin. Accumulating evidence suggests that AD is caused by genetic factors, environmental exposure and immune system dysfunction; however, its underlying molecular mechanism remains unclear. Current treatment strategies aim to decrease the severity and frequency of flares. Heme oxygenase-1 (HO-1) is a nuclear factor erythroid 2-related factor 2 (Nrf2)-regulated gene that plays crucial roles against stress, inflammation and oxidation, and exerts cytoprotective effects. Previous studies have reported that treatment of AD induces high expression levels of HO-1 and Nrf2, indicating that HO-1 may play an important role in the treatment of AD. The present study constructed the recombinant protein, cell-p enetrating peptide-HO-1 (CPP-HO-1), which was expressed in Escherichia coli and isolated with a 6xHis-tag using HiTrap His column (1 ml). AD was established using 4-dinitrochlorobenzene (DNCB) in mice. It was observed that the CPP-HO-1 fusion protein decreased the severity of AD, inhibited scratching in mice and decreased skin inflammation. Taken together, the results of the present study suggested that the CPP-HO-1 fusion protein may play a protective role against DNCB-induced AD in mice. PMID:34306205 | PMC:PMC8281355 | DOI:10.3892/etm.2021.10373 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.